TPWA
SGMO

Twin Peaks Wealth Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$247 Buy
+1,000
New +$398 ﹤0.01% 2144
2025
Q3 		– Sell
-1,000
Closed -$518 – 1762
2025
Q2 		$518 Buy
+1,000
New +$594 ﹤0.01% 1909

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Twin Peaks Wealth Advisors's SGMO Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026: 1,000 shares worth $247. The stake represents ﹤0.01% of the portfolio and ranks #2144 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in SGMO as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in SGMO in Q2 2025 and has held it in 2 quarters since. The position peaked at $518 in Q2 2025. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Twin Peaks Wealth Advisors held 1,000 shares of SANGAMO THERAPEUTICS INC worth $247 as of Q1 2026.
  • SANGAMO THERAPEUTICS INC was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2144 holding.
  • Twin Peaks Wealth Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q2 2025 and has held it in 2 quarters since.
  • Twin Peaks Wealth Advisors's SANGAMO THERAPEUTICS INC position peaked at $518 in Q2 2025.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.